BridgeBio's encaleret shows symptom gains in ADH1 phase 3 trial

October 11, 2026 11:42 AM

BridgeBio Pharma (Nasdaq: BBIO) presented data from its Phase 3 CALIBRATE trial of encaleret in autosomal dominant hypocalcemia type 1 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found